Recent advance of next-generation sequencing in patients with lung cancer

References

• Zhou C, Wu YL, Chen G, et al. Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802). Ann Oncol. 2015;26(9):1877–1883. doi: 10.1093/annonc/mdv276
   PubMed Web of Science ®Google Scholar
• Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or platinum-pemetrexed in EGFR T790M-Positive lung cancer. N Engl J Med. 2017 Feb 16;376(7):629–640. doi: 10.1056/NEJMoa1612674
   PubMed Web of Science ®Google Scholar
• He J, Su C, Liang W, et al. Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial. Lancet Respir Med. 2021 Sep;9(9):1021–1029. doi: 10.1016/S2213-2600(21)00134-X
   PubMed Web of Science ®Google Scholar
• Tsuboi M, Herbst RS, John T, et al. Overall survival with osimertinib in resected EGFR-mutated NSCLC. N Engl J Med. 2023 Jul 13;389(2):137–147. doi: 10.1056/NEJMoa2304594
   PubMed Web of Science ®Google Scholar
• Reck M, Rodriguez-Abreu D, Robinson AG, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50%. J Clin Oncol. 2021;39(21):2339±. doi: 10.1200/JCO.21.00174
   Web of Science ®Google Scholar
• de Castro G, Kudaba I, Wu YL, et al. 363 KEYNOTE-042 5-year survival update: pembrolizumab versus chemotherapy in patients with previously untreated, PD-L1–positive, locally advanced or metastatic non–small-cell lung cancer. J Immunother Cancer. 2021;9(Suppl 2):A390–A390. doi: 10.1136/jitc-2021-SITC2021.363
   Google Scholar
• Felip E, Altorki N, Zhou C, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB-IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2021;398(10308):1344–1357. doi: 10.1016/S0140-6736(21)02098-5
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wu YL, Chen KN, et al. CTONG 1103: erlotinib versus gemcitabine plus cisplatin as neo-adjuvant treatment for stage IIIA-N2 EGFR-mutation non- small cell lung cancer (EMERGING): a randomised study. Ann Oncol. 2018;29:738–738. doi: 10.1093/annonc/mdy424.058
   Web of Science ®Google Scholar
• Hirsch FR, Kerr KM, Bunn PA, et al. Molecular and immune biomarker testing in squamous-cell lung cancer: effect of Current and future therapies and technologies. Clin Lung Cancer. 2018;19(4):331–339. doi: 10.1016/j.cllc.2018.03.014
   PubMed Web of Science ®Google Scholar
• Kris MG, Johnson BE, Berry LD, et al. Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. J Am Med Assoc. 2014;311(19):1998–2006. doi: 10.1001/jama.2014.3741
   PubMed Web of Science ®Google Scholar
• Chang ZT, Chan TM, Wu CE. EGFR T751_I759delinsN mutation in Exon19 detected by NGS but not by real-time PCR in a heavily-treated patient with NSCLC. Int J Mol Sci. 2022;23(21):13451. doi: 10.3390/ijms232113451
   PubMed Web of Science ®Google Scholar
• He CL, Wei CC, Wen J, et al. Comprehensive analysis of NGS and ARMS-PCR for detecting EGFR mutations based on 4467 cases of NSCLC patients. J Cancer Res Clin Oncol. 2022;148(2):321–330. doi: 10.1007/s00432-021-03818-w
   PubMed Web of Science ®Google Scholar
• Dall’olio FG, Conci N, Rossi G, et al. Comparison of sequential testing and next generation sequencing in advanced lung adenocarcinoma patients - a single centre experience. Lung Cancer. 2020;149:5–9. doi: 10.1016/j.lungcan.2020.08.008
   PubMed Web of Science ®Google Scholar
• Cohen D, Hondelink LM, Solleveld-Westerink N, et al. Optimizing mutation and fusion detection in NSCLC by sequential DNA and RNA sequencing. J Thorac Oncol. 2020;15(6):1000–1014.*. doi: 10.1016/j.jtho.2020.01.019
   PubMed Web of Science ®Google Scholar
• Benayed R, Offin M, Mullaney K, et al. High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden. Clin Cancer Res. 2019;25(15):4712–4722. doi: 10.1158/1078-0432.CCR-19-0225
   PubMed Web of Science ®Google Scholar
• Kemper M, Krekeler C, Menck K, et al. Liquid biopsies in lung cancer. Cancers. 2023;15(5):1430.
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic—implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.*. doi: 10.1038/s41571-020-00457-x
   PubMed Web of Science ®Google Scholar
• Cheng ML, Milan MSD, Tamen RM, et al. Plasma cfDNA genotyping in hospitalized patients with suspected metastatic NSCLC. JCO Precision Oncol. 2021;5(5):726–732. doi: 10.1200/PO.21.00029
   PubMedGoogle Scholar
• Li W, Liu JB, Hou LK, et al. Liquid biopsy in lung cancer: significance in diagnostics, prediction, and treatment monitoring. Mol Cancer. 2022;21(1): doi: 10.1186/s12943-022-01505-z
   Web of Science ®Google Scholar
• Leighl NB, Page RD, Raymond VM, et al. Clinical utility of comprehensive cell-free DNA analysis to identify genomic biomarkers in patients with newly diagnosed metastatic non-small cell lung cancer. Clin Cancer Res. 2019;25(15):4691–4700. doi: 10.1158/1078-0432.CCR-19-0624
   PubMed Web of Science ®Google Scholar
• Cui WY, Milner-Watts C, O’Sullivan H, et al. Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients. Eur J Cancer. 2022;171:44–54. doi: 10.1016/j.ejca.2022.05.012
   PubMed Web of Science ®Google Scholar
• Malapelle U, Pisapia P, Rocco D, et al. Next generation sequencing techniques in liquid biopsy: focus on non-small cell lung cancer patients. Transl Lung Cancer Res. 2016;5(5):505–510. doi: 10.21037/tlcr.2016.10.08
   PubMed Web of Science ®Google Scholar
• Muzzey D, Kash S, Johnson JI, et al. Software-assisted manual review of clinical next-generation sequencing data an alternative to routine sanger sequencing confirmation with equivalent results in > 15,000 germline DNA screens. J Mol Diagn. 2019;21(2):296–306. doi: 10.1016/j.jmoldx.2018.10.002
   PubMed Web of Science ®Google Scholar
• Ettinger DS, Wood DE, Aisner DL, et al. Non-small cell lung cancer, version 3.2022. J National Compr Cancer Network. 2022;20(5):497–530. doi: 10.6004/jnccn.2022.0025
   PubMed Web of Science ®Google Scholar
• Mosele F, Remon J, Mateo J, et al. Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO precision medicine working group. Ann Oncol. 2020;31(11):1491–1505. doi: 10.1016/j.annonc.2020.07.014
   PubMed Web of Science ®Google Scholar
• Illei PB, Belchis D, Tseng LH, et al. Clinical mutational profiling of 1006 lung cancers by next generation sequencing. Oncotarget. 2017;8(57):96684–96696. doi: 10.18632/oncotarget.18042
   PubMedGoogle Scholar
• Zhou XY, Xu XH, Tian ZH, et al. Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing. J Cancer Res Clin Oncol. 2020;146(9):2277–2287. doi: 10.1007/s00432-020-03284-w
   PubMed Web of Science ®Google Scholar
• Zulato E, Tosello V, Nardo G, et al. Implementation of next generation sequencing-based liquid biopsy for clinical molecular Diagnostics in non-small cell lung cancer (NSCLC) patients. Diagnostics. 2021;11(8):1468. doi: 10.3390/diagnostics11081468
   Web of Science ®Google Scholar
• Francaviglia I, Magliacane G, Lazzari C, et al. Identification and monitoring of somatic mutations in circulating cell-free tumor DNA in lung cancer patients. Lung Cancer. 2019;134:225–232. doi: 10.1016/j.lungcan.2019.06.010
   PubMed Web of Science ®Google Scholar
• Bayle A, Belcaid L, Aldea M, et al. Clinical utility of circulating tumor DNA sequencing with a large panel: a National center for precision medicine (PRISM) study. Ann Oncol. 2023;34(4):389–396. doi: 10.1016/j.annonc.2023.01.008
   PubMed Web of Science ®Google Scholar
• Gibert J, Clave S, Hardy-Werbin M, et al. Concomitant genomic alterations in KRAS mutant advanced lung adenocarcinoma. Lung Cancer. 2020;140:42–45. doi: 10.1016/j.lungcan.2019.12.003
   PubMed Web of Science ®Google Scholar
• Hong SD, Gao FF, Fu S, et al. Concomitant genetic alterations with response to treatment and epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR-Mutant advanced non-small cell lung cancer. JAMA Oncol. 2018;4(5):739–742. doi: 10.1001/jamaoncol.2018.0049
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Cheng Y, An TT, et al. Detection of EGFR mutations in plasma circulating tumour DNA as a selection criterion for first-line gefitinib treatment in patients with advanced lung adenocarcinoma (BENEFIT): a phase 2, single-arm, multicentre clinical trial. Lancet Respir Med. 2018;6(9):681–690. doi: 10.1016/S2213-2600(18)30264-9
   PubMed Web of Science ®Google Scholar
• Herbst RS, Garon EB, Kim DW, et al. Five year survival update from KEYNOTE-010: pembrolizumab versus docetaxel for previously treated, programmed death-ligand 1-positive advanced NSCLC. J Thorac Oncol. 2021;16(10):1718–1732.
   PubMed Web of Science ®Google Scholar
• Mok TSK, Wu YL, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393(10183):1819–1830. doi: 10.1016/S0140-6736(18)32409-7
   PubMed Web of Science ®Google Scholar
• Sezer A, Kilickap S, Gumus M, et al. Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial. Lancet. 2021;397(10274):592–604. doi: 10.1016/S0140-6736(21)00228-2
   PubMed Web of Science ®Google Scholar
• Chan TA, Yarchoan M, Jaffee E, et al. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic. Ann Oncol. 2019;30(1):44–56. doi: 10.1093/annonc/mdy495
   PubMed Web of Science ®Google Scholar
• Wang ZJ, Wu L, Li BL, et al. Toripalimab plus chemotherapy for patients with treatment-naive advanced non-small-cell lung cancer: a multicenter randomized phase III trial (CHOICE-01). J Clin Oncol. 2023;41(3):651±. doi: 10.1200/JCO.22.00727
   Web of Science ®Google Scholar
• Zhou CC, Chen GY, Huang YC, et al. Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL): a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021;9(3):305–314. doi: 10.1016/S2213-2600(20)30365-9
   PubMed Web of Science ®Google Scholar
• Ren SX, Chen JH, Xu X X, et al. Camrelizumab plus carboplatin and paclitaxel as first-line treatment for advanced squamous NSCLC (CameL-Sq): a phase 3 trial. J Thorac Oncol. 2022;17(4):544–557. doi: 10.1016/j.jtho.2021.11.018
   PubMed Web of Science ®Google Scholar
• Fang WF, Ma YX, Yin JNC, et al. Comprehensive genomic profiling identifies novel genetic predictors of response to anti-PD-(L)1 therapies in non-small cell lung cancer. Clin Cancer Res. 2019;25(16):5015–5026. doi: 10.1158/1078-0432.CCR-19-0585
   PubMed Web of Science ®Google Scholar
• Ricciuti B, Arbour KC, Lin JJ, et al. Diminished efficacy of programmed death-(Ligand)1 inhibition in STK11- and KEAP1-mutant lung adenocarcinoma is affected by KRAS mutation status. J Thorac Oncol. 2022;17(3):399–410. doi: 10.1016/j.jtho.2021.10.013
   PubMed Web of Science ®Google Scholar
• Skoulidis F, Goldberg ME, Greenawalt DM, et al. STK11/LKB1 mutations and PD-1 inhibitor resistance in KRAS-mutant lung adenocarcinoma. Cancer Discov. 2018;8(7):822–835. doi: 10.1158/2159-8290.CD-18-0099
   PubMed Web of Science ®Google Scholar
• Mino-Kenudson M, Schalper K, Cooper W, et al. Predictive biomarkers for immunotherapy in lung cancer: perspective from the International association for the study of lung cancer pathology committee. J Thorac Oncol. 2022;17(12):1335–1354. doi: 10.1016/j.jtho.2022.09.109
   PubMed Web of Science ®Google Scholar
• Meri-Abad M, Moreno-Manuel A, Garcia SG, et al. Clinical and technical insights of tumour mutational burden in non-small cell lung cancer. Crit Rev Oncol Hematol. 2023;182:103891. doi: 10.1016/j.critrevonc.2022.103891
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Chen KN, Chen C, et al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-Mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized phase II study. J Clin Oncol. 2019;37(25):2235–2245. doi: 10.1200/JCO.19.00075
   PubMed Web of Science ®Google Scholar
• Herbst RS, Wu YL, John T, et al. Adjuvant osimertinib for resected EGFR-Mutated stage IB-IIIA non-small-cell lung cancer: updated results from the phase III randomized ADAURA trial. J Clin Oncol. 2023;41(10):1830–1840. doi: 10.1200/JCO.22.02186
   PubMed Web of Science ®Google Scholar
• Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: final overall survival analysis of CTONG1104 phase III trial. J Clin Oncol. 2021;39(7):713–722. doi: 10.1200/JCO.20.01820
   PubMed Web of Science ®Google Scholar
• Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863–873. doi: 10.1016/S2213-2600(18)30277-7
   PubMed Web of Science ®Google Scholar
• Goss GD, O’Callaghan C, Lorimer I, et al. Gefitinib versus placebo in completely resected non-small-cell lung cancer: results of the NCIC CTG BR19 study. J Clin Oncol. 2013;31(27):3320–3326. doi: 10.1200/JCO.2013.51.1816
   PubMed Web of Science ®Google Scholar
• Kelly K, Altorki NK, Eberhardt WE, et al. Adjuvant Erlotinib versus placebo in patients with stage IB-IIIA non-small-cell lung cancer (RADIANT): a randomized, Double-blind, phase III trial. J Clin Oncol. 2015;33(34):4007–4014. doi: 10.1200/JCO.2015.61.8918
   PubMed Web of Science ®Google Scholar
• Provencio M, Serna-Blasco R, Nadal E, et al. Overall survival and biomarker analysis of neoadjuvant nivolumab plus chemotherapy in operable stage IIIA non-small-cell lung cancer (NADIM phase II trial). J Clin Oncol. 2022;40(25):2924–2933. doi: 10.1200/JCO.21.02660
   PubMed Web of Science ®Google Scholar
• Chaft JE, Oezkan F, Kris MG, et al. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial. Nat Med. 2022;28(10):2155–2161. doi: 10.1038/s41591-022-01962-5
   PubMed Web of Science ®Google Scholar
• Cascone T, Leung CH, Weissferdt A, et al. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med. 2023;29(3):593–604. doi: 10.1038/s41591-022-02189-0
   PubMedGoogle Scholar
• Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med. 2022;386(21):1973–1985.
   PubMed Web of Science ®Google Scholar
• O’Brien M, Paz-Ares L, Marreaud S, et al. Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022;23(10):1274–1286. doi: 10.1016/S1470-2045(22)00518-6
   PubMed Web of Science ®Google Scholar
• Wakelee H, Liberman M, Kato T, et al. Perioperative pembrolizumab for early-stage non-small-cell lung cancer. N Engl J Med. 2023;389(6):491–503. doi: 10.1056/NEJMoa2302983
   PubMed Web of Science ®Google Scholar
• Shi LT, He YY, Yuan ZL, et al. Radiomics for response and outcome assessment for non-small cell lung cancer. Technol Cancer Res Treat. 2018;17:17. doi: 10.1177/1533033818782788
   Web of Science ®Google Scholar
• Guibert N, Pradines A, Favre G, et al. Current and future applications of liquid biopsy in nonsmall cell lung cancer from early to advanced stages. Eur Respir Rev. 2020;29(155):190052. doi: 10.1183/16000617.0052-2019
   PubMed Web of Science ®Google Scholar
• Esposito A, Criscitiello C, Trapani D, et al. The emerging role of “liquid biopsies,” circulating tumor cells, and circulating cell-free tumor DNA in lung cancer diagnosis and identification of resistance mutations. Curr Oncol Rep. 2017;19(1): doi: 10.1007/s11912-017-0564-y
   PubMed Web of Science ®Google Scholar
• Diao ZL, Han YX, Zhang R, et al. Circulating tumour DNA: a new biomarker to monitor resistance in NSCLC patients treated with EGFR-TKIs. Biochim Et Biophys Acta-Reviews Cancer. 2020;1873(2):188363. doi: 10.1016/j.bbcan.2020.188363
   PubMed Web of Science ®Google Scholar
• Kunimasa K, Nishino K, Sato Y, et al. Fragment size and dynamics of EGFR-mutated tumor-derived DNA provide prognostic information regarding EGFR-TKI efficacy in patients with EGFR-mutated NSCLC. Sci Rep. 2022;12(1): doi: 10.1038/s41598-022-17848-y
   Web of Science ®Google Scholar
• Ryu WK, Oh S, Lim JH, et al. Monitoring circulating tumor DNA in untreated non-small-cell lung cancer patients. Int J Mol Sci. 2022;23(17):9527. doi: 10.3390/ijms23179527
   PubMed Web of Science ®Google Scholar
• Moding EJ, Diehn M and Wakelee HA. Circulating tumor DNA testing in advanced non-small cell lung cancer. Lung Cancer. 2018;119:42–47. doi: 10.1016/j.lungcan.2018.02.019
   PubMed Web of Science ®Google Scholar
• Corcoran RB, Chabner BA. Application of cell-free DNA analysis to cancer treatment. N Engl J Med. 2018;379(18):1754–1765. doi: 10.1056/NEJMra1706174
   PubMed Web of Science ®Google Scholar
• Jebbink M, van der Wel JWT, van den Broek D, et al. Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to second-line osimertinib treatment in patients with EGFR mutation positive (EGFRm) NSCLC. Ann Oncol. 2021;32:S1202–S1202. doi: 10.1016/j.annonc.2021.08.1984
   Google Scholar
• Kim C, Xi LQ, Cultraro CM, et al. Longitudinal circulating tumor DNA analysis in blood and saliva for prediction of response to osimertinib and disease progression in EGFR-Mutant lung adenocarcinoma. Cancers. 2021;13(13):3342. doi: 10.3390/cancers13133342
   PubMed Web of Science ®Google Scholar
• Song Y, Ma SL, Shi MQ, et al. Predictive and prognostic values of circulating tumor DNA (ctDNA) clearance in osimertinib treated advanced non-small cell lung cancer cohort. J Clin Oncol. 2019;37(15):3036–3036. doi: 10.1200/JCO.2019.37.15_suppl.3036
   Web of Science ®Google Scholar
• Papadimitrakopoulou VA, Han JY, Ahn MJ, et al. Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer. Cancer. 2020;126(2):373–380. doi: 10.1002/cncr.32503
   PubMed Web of Science ®Google Scholar
• Gray JE, Peled N, Markovets A, et al. Longitudinal circulating tumour DNA (ctDNA) monitoring for early detection of disease progression and resistance in advanced NSCLC in FLAURA. Ann Oncol. 2019;30:921±. doi: 10.1093/annonc/mdz394.083
   PubMedGoogle Scholar
• Hartmaier RJ, Markovets AA, Ahn MJ, et al. Osimertinib plus savolitinib to overcome acquired MET-Mediated resistance in epidermal growth factor receptor-mutated, MET-Amplified non-small cell lung cancer: TATTON. Cancer Discov. 2023;13(1):98–113. doi: 10.1158/2159-8290.CD-22-0586
   PubMed Web of Science ®Google Scholar
• Rolfo C, Mack P, Scagliotti GV, et al. Liquid biopsy for advanced NSCLC: a consensus Statement from the International association for the study of lung cancer. J Thorac Oncol. 2021;16(10):1647–1662. doi: 10.1016/j.jtho.2021.06.017
   PubMed Web of Science ®Google Scholar
• Chen MY, Zeng YC. Pseudoprogression in lung cancer patients treated with immunotherapy. Crit Rev Oncol Hematol. 2022;169:169. doi: 10.1016/j.critrevonc.2021.103531
   Web of Science ®Google Scholar
• Thompson JC, Carpenter EL, Silva BA, et al. Serial monitoring of circulating tumor DNA by next-generation gene sequencing as a biomarker of response and survival in patients with advanced NSCLC receiving pembrolizumab-based therapy. JCO Precision Oncol. 2021;5(5):510–524. doi: 10.1200/PO.20.00321
   Google Scholar
• Assaf ZJF, Zou W, Fine AD, et al. A longitudinal circulating tumor DNA-based model associated with survival in metastatic non-small-cell lung cancer. Nat Med. 2023;29(4):859–868. doi: 10.1038/s41591-023-02226-6
   PubMedGoogle Scholar
• Zulato E, Del Bianco P, Nardo G, et al. Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors. Br J Cancer. 2022;127(11):2034–2042. doi: 10.1038/s41416-022-01978-1
   PubMed Web of Science ®Google Scholar
• Fu FQ, Zhou YD, Zhang Y, et al. Lung cancer screening strategy for non-high-risk individuals: a narrative review. Transl Lung Cancer Res. 2021;10(1):452–461. doi: 10.21037/tlcr-20-943
   PubMed Web of Science ®Google Scholar
• Li CC, Wang HT, Jiang Y, et al. Advances in lung cancer screening and early detection. Cancer Biol Ther. 2022;19(5):591–608. doi: 10.20892/j.issn.2095-3941.2021.0690
   Google Scholar
• Arbour KC, Riely GJ. Systemic therapy for locally advanced and metastatic non-small cell lung cancer a review. J Am Med Assoc. 2019;322(8):764–774. doi: 10.1001/jama.2019.11058
   PubMed Web of Science ®Google Scholar
• Santarpia M, Liguori A, D’Aveni A, et al. Liquid biopsy for lung cancer early detection. J Thoracic Dis. 2018;10(S7):S882–S897. doi: 10.21037/jtd.2018.03.81
   PubMedGoogle Scholar
• Chabon JJ, Hamilton EG, Kurtz DM, et al. Integrating genomic features for non-invasive early lung cancer detection. Nature. 2020;580(7802):245±.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Swanton C. Early stage NSCLC - challenges to implementing ctDNA-based screening and MRD detection. Nat Rev Clin Oncol. 2018;15(9):577–586. doi: 10.1038/s41571-018-0058-3
   PubMed Web of Science ®Google Scholar
• Paiva B, van Dongen JJ, Orfao A. New criteria for response assessment: role of minimal residual disease in multiple myeloma. Blood. 2015;125(20):3059–3068. doi: 10.1182/blood-2014-11-568907
   PubMed Web of Science ®Google Scholar
• Berry DA, Zhou S, Higley H, et al. Association of minimal residual disease with clinical outcome in pediatric and adult acute lymphoblastic leukemia: a meta-analysis. JAMA Oncol. 2017;3(7):e170580.
   PubMed Web of Science ®Google Scholar
• Rothwell DG, Ayub M, Cook N, et al. Utility of ctDNA to support patient selection for early phase clinical trials: the TARGET study. Nat Med. 2019;25(5):738–743. doi: 10.1038/s41591-019-0380-z
   PubMed Web of Science ®Google Scholar
• Garcia-Murillas I, Chopra N, Comino-Méndez I, et al. Assessment of molecular relapse detection in early-stage breast cancer. JAMA Oncol. 2019;5(10):1473–1478.
   PubMed Web of Science ®Google Scholar
• Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma cell-free DNA by ultradeep sequencing in patients with stages I to III colorectal cancer. JAMA Oncol. 2019;5(8):1124–1131.
   PubMed Web of Science ®Google Scholar
• Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545(7655):446–451. doi: 10.1038/nature22364
   PubMed Web of Science ®Google Scholar
• Pellini B, Chaudhuri AA. Circulating tumor DNA minimal residual disease detection of non-small-cell lung cancer treated with curative intent. J Clin Oncol. 2022;40(6):567–575. doi: 10.1200/JCO.21.01929
   PubMed Web of Science ®Google Scholar
• Abbosh C, Frankell AM, Harrison T, et al. Tracking early lung cancer metastatic dissemination in TRACERx using ctDNA. Nature. 2023;616(7957):553–562.
   PubMed Web of Science ®Google Scholar
• Zhang JT, Liu SY, Gao W, et al. Longitudinal undetectable molecular residual disease defines potentially cured population in localized non-small cell lung cancer. Cancer Discov. 2022;12(7):1690–1701.**. doi: 10.1158/2159-8290.CD-21-1486
   PubMed Web of Science ®Google Scholar
• Qiu B, Guo W, Zhang F, et al. Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC. Nat Commun. 2021;12(1):6770.
   PubMed Web of Science ®Google Scholar
• Kuang PP, Li N, Liu Z, et al. Circulating tumor DNA analyses as a potential marker of recurrence and effectiveness of adjuvant chemotherapy for resected non-small-cell lung cancer. Front Oncol. 2020;10:595650. doi: 10.3389/fonc.2020.595650
   PubMed Web of Science ®Google Scholar
• Xia L, Mei J, Kang R, et al. Perioperative ctDNA-Based molecular residual disease detection for non-small cell lung cancer: a prospective multicenter cohort study (LUNGCA-1). Clin Cancer Res. 2022;28(15):3308–3317. doi: 10.1158/1078-0432.CCR-21-3044
   PubMed Web of Science ®Google Scholar
• Wu YL, Lu S, Cheng Y, et al. Expert consensus of molecular residual disease for non-small cell lung cancer. Chin J Evidence-Based Med. 2021;21(2):129–135.
   Google Scholar
• Moding EJ, Liu Y, Nabet BY, et al. Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small cell lung cancer. Nat Cancer. 2020;1(2):176–183. doi: 10.1038/s43018-019-0011-0
   PubMedGoogle Scholar
• Chaudhuri AA, Chabon JJ, Lovejoy AF, et al. Early detection of molecular residual disease in localized lung cancer by circulating tumor DNA profiling. Cancer Discov. 2017;7(12):1394–1403. doi: 10.1158/2159-8290.CD-17-0716
   PubMed Web of Science ®Google Scholar
• Horn L, Mansfield AS, Szczęsna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379(23):2220–2229. doi: 10.1056/NEJMoa1809064
   PubMed Web of Science ®Google Scholar
• Goldman JW, Dvorkin M, Chen Y, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):51–65. doi: 10.1016/S1470-2045(20)30539-8
   PubMed Web of Science ®Google Scholar
• Febres-Aldana CA, Chang JC, Ptashkin R, et al. Rb tumor suppressor in small cell lung cancer: combined genomic and IHC analysis with a description of a distinct Rb-proficient subset. Clin Cancer Res. 2022;28(21):4702–4713. doi: 10.1158/1078-0432.CCR-22-1115
   PubMed Web of Science ®Google Scholar
• Larson NB, Oberg AL, Adjei AA, et al. A clinician’s guide to bioinformatics for next-generation sequencing. J Thorac Oncol. 2023;18(2):143–157. doi: 10.1016/j.jtho.2022.11.006
   PubMed Web of Science ®Google Scholar
• Singh RR. Next-generation sequencing in high-sensitive detection of mutations in tumors challenges, advances, and applications. J Mol Diagn. 2020;22(8):994–1007. doi: 10.1016/j.jmoldx.2020.04.213
   PubMed Web of Science ®Google Scholar
• Zhang YC. Zhou Q and Wu YL the emerging roles of NGS-based liquid biopsy in non-small cell lung cancer. J Hematol Oncol. 2017;10(1):10. doi: 10.1186/s13045-017-0536-6
   PubMedGoogle Scholar
• Filipska M, Rosell R. Mutated circulating tumor DNA as a liquid biopsy in lung cancer detection and treatment. Mol Oncol. 2021;15(6):1667–1682. doi: 10.1002/1878-0261.12983
   PubMed Web of Science ®Google Scholar
• Ignatiadis M, Sledge GW, Jeffrey SS. Liquid biopsy enters the clinic - implementation issues and future challenges. Nat Rev Clin Oncol. 2021;18(5):297–312.
   PubMed Web of Science ®Google Scholar
• Athanasopoulou K, Boti MA, Adamopoulos PG, et al. Third-generation sequencing: the spearhead towards the radical transformation of modern genomics. Life-Basel. 2022;12(1):30. doi: 10.3390/life12010030
   Web of Science ®Google Scholar
• McGinn S, Gut IG. DNA sequencing - spanning the generations. New Biotechnology. 2013;30(4):366–372. doi: 10.1016/j.nbt.2012.11.012
   PubMed Web of Science ®Google Scholar
• Liam CK, Mallawathantri S, Fong KM. Is tissue still the issue in detecting molecular alterations in lung cancer? Respirology. 2020;25(9):933–943. doi: 10.1111/resp.13823
   PubMed Web of Science ®Google Scholar
• Chen KZ, Zhao H, Shi YB, et al. Perioperative dynamic changes in circulating tumor DNA in patients with lung cancer (DYNAMIC). Clin Cancer Res. 2019;25(23):7058–7067. doi: 10.1158/1078-0432.CCR-19-1213
   PubMed Web of Science ®Google Scholar
• Martínez-Ruiz C, Black JRM, Puttick C, et al. Genomic-transcriptomic evolution in lung cancer and metastasis. Nature. 2023;616(7957):543–552. doi: 10.1038/s41586-023-05706-4
   PubMed Web of Science ®Google Scholar
• Al Bakir M, Huebner A, Martínez-Ruiz C, et al. The evolution of non-small cell lung cancer metastases in TRACERx. Nature. 2023;616(7957):534–542.**. doi: 10.1038/s41586-023-05729-x
   PubMed Web of Science ®Google Scholar
• Frankell AM, Dietzen M, Al Bakir M, et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature. 2023;616(7957):525–533.**. doi: 10.1038/s41586-023-05783-5
   PubMed Web of Science ®Google Scholar
• Marcus L, Fashoyin-Aje LA, Donoghue M, et al. FDA approval summary: pembrolizumab for the treatment of tumor mutational burden-high solid for tumors. Clin Cancer Res. 2021;27(17):4685–4689.
   PubMed Web of Science ®Google Scholar
• Cristescu R, Aurora-Garg D, Albright A, et al. Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors. J Immunother Cancer. 2022;10(1): doi: 10.1136/jitc-2021-003091
   Web of Science ®Google Scholar
• Sholl LM, Hirsch FR, Hwang D, et al. The promises and challenges of tumor mutation burden as an immunotherapy biomarker: a perspective from the international association for the study of lung cancer pathology committee. J Thorac Oncol. 2020;15(9):1409–1424.
   PubMed Web of Science ®Google Scholar
• Liu SV, Horn L, Mok T, et al. IMpower133: characterisation of long-term survivors treated first-line with chemotherapy ± atezolizumab in extensive-stage small cell lung cancer. Ann Oncol. 2020;31:S1032–S1033. doi: 10.1016/j.annonc.2020.08.1543
   Web of Science ®Google Scholar
• Peters S, Dziadziuszko R, Morabito A, et al. Atezolizumab versus chemotherapy in advanced or metastatic NSCLC with high blood-based tumor mutational burden: primary analysis of BFAST cohort C randomized phase 3 trial. Nature Med. 2022;28(9):1831±. doi: 10.1038/s41591-022-01933-w
   Web of Science ®Google Scholar
• Langer C, Gadgeel S, Borghaei H, et al. KEYNOTE-021: TMB and outcomes for carboplatin and pemetrexed with or without pembrolizumab for nonsquamous NSCLC. J Thorac Oncol. 2019;14(10):S216–S216.
   Web of Science ®Google Scholar
• Wang ZJ, Duan JC, Wang GQ, et al. Allele frequency-adjusted blood-based tumor mutational burden as a predictor of overall survival for patients with NSCLC treated with PD-(L)1 inhibitors. J Thorac Oncol. 2020;15(4):556–567.*. doi: 10.1016/j.jtho.2019.12.001
   PubMed Web of Science ®Google Scholar
• Liu ZC, Xie ZH, Cai XY, et al. A modi fied algorithm adjusting both high and minor allele frequency mutation to rede fine blood-based tumor mutational burden (bTMB) for optimal prediction of clinical bene fits from immune checkpoint inhibitor therapy. J Thorac Oncol. 2020;15(5):E69–E72. doi: 10.1016/j.jtho.2019.12.120
   PubMed Web of Science ®Google Scholar
• Jiang T, Chen JH, Xu XX, et al. On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial. Mol Cancer. 2022;21(1):4. doi: 10.1186/s12943-021-01479
   PubMed Web of Science ®Google Scholar
• Cuppens K, Baas P, Geerdens E, et al. HLA-I diversity and tumor mutational burden by comprehensive next-generation sequencing as predictive biomarkers for the treatment of non-small cell lung cancer with PD-(L)1 inhibitors. Lung Cancer. 2022;170:1–10. doi: 10.1016/j.lungcan.2022.05.019
   PubMed Web of Science ®Google Scholar
• McGranahan N, Rosenthal R, Hiley CT, et al. Allele-specific HLA loss and immune escape in lung cancer evolution. Cell. 2017;171(6):1259±. doi: 10.1016/j.cell.2017.10.001
   PubMed Web of Science ®Google Scholar